Your browser doesn't support javascript.
loading
Antibody Persistence up to 3 Years After Primary Immunization With Inactivated Japanese Encephalitis Vaccine IXIARO in Philippine Children and Effect of a Booster Dose.
Kadlecek, Vera; Borja-Tabora, Charissa Fay; Eder-Lingelbach, Susanne; Gatchalian, Salvacion; Kiermayr, Sigrid; Sablan, Benjamin; Kundi, Michael; Taucher, Christian; Dubischar, Katrin L.
Afiliação
  • Kadlecek V; From the Valneva Austria GmbH, Vienna, Austria.
  • Borja-Tabora CF; Department of Health, Research Institute for Tropical Medicine, Manila, Philippines.
  • Eder-Lingelbach S; From the Valneva Austria GmbH, Vienna, Austria.
  • Gatchalian S; Department of Pediatrics.
  • Kiermayr S; College of Medicine, University of the Philippines, Manila, Philippines.
  • Sablan B; Section of Infectious and Tropical Diseases, Department of Pediatrics, Philippine General Hospital, Manila, Philippines.
  • Kundi M; Department of Health, Research Institute for Tropical Medicine, Muntinlupa, Philippines.
  • Taucher C; From the Valneva Austria GmbH, Vienna, Austria.
  • Dubischar KL; Department of Pediatrics.
Pediatr Infect Dis J ; 37(9): e233-e240, 2018 09.
Article em En | MEDLINE | ID: mdl-29912844
BACKGROUND: An inactivated Vero cell culture derived Japanese encephalitis virus vaccine (IXIARO) requires a booster dose 1 year after primary schedule for long-term antibody persistence in adults. The aim of this study is to evaluate immunogenicity and safety of a booster dose in children 2 months to <18 years of age. METHODS: This is a randomized, controlled open-label study in the Philippines. Three hundred children vaccinated with IXIARO in a previous trial were randomized 1:1 to receive either no booster or a booster 12 months after initiation of the primary series. Neutralizing antibody titers were assessed before and after the booster and up to 3 years after primary series. Safety endpoints included the rate of subjects with solicited adverse events (AEs), unsolicited AEs and serious AEs within 1 month after the booster. RESULTS: Geometric mean titer declined by 1 year after the primary series, but titers remained above the established protective threshold in 85%-100% of children depending on age group. The booster led to a pronounced increase in geometric mean titer and 100% seroprotection rate in all age groups. The booster was well tolerated, with AE rates lower compared with the primary series. Most AEs were mild. CONCLUSIONS: A booster dose of IXIARO administered 12 months after the primary immunization was well tolerated and highly immunogenic.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encefalite Japonesa / Vacinas contra Encefalite Japonesa / Imunogenicidade da Vacina / Anticorpos Antivirais Tipo de estudo: Clinical_trials Limite: Adolescent / Child / Child, preschool / Humans / Infant / Male País/Região como assunto: Asia Idioma: En Revista: Pediatr Infect Dis J Assunto da revista: DOENCAS TRANSMISSIVEIS / PEDIATRIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Áustria

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encefalite Japonesa / Vacinas contra Encefalite Japonesa / Imunogenicidade da Vacina / Anticorpos Antivirais Tipo de estudo: Clinical_trials Limite: Adolescent / Child / Child, preschool / Humans / Infant / Male País/Região como assunto: Asia Idioma: En Revista: Pediatr Infect Dis J Assunto da revista: DOENCAS TRANSMISSIVEIS / PEDIATRIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Áustria